Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PVSRIPO and Nivolumab in PD-1 Refractory Melanoma
NCT04125719Phase 1Withdrawn
- Sponsor
- Istari Oncology
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 1, open-label trial of lerapolturev in melanoma (2 arms), sponsored by Istari Oncology. Primary endpoint: Adverse Events at 36 months. Planned start Jun 2020; status: withdrawn.
02
Drugs
lerapolturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04125719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04125719.